New M, L, and T Dwarf Companions to Nearby Stars from the Wide-field Infrared Survey Explorer

We present 11 candidate late-type companions to nearby stars identified with data from the Wide-field Infrared Survey Explorer (WISE) and the Two Micron All Sky Survey (2MASS). Eight of the candidates are likely to be companions based on their common proper motions with the primaries. The remaining three objects are rejected as companions, one of which is a free-floating T7 dwarf. Spectral types are available for five of the companions, which consist of M2V, M8.5V, L5, T8, and T8. Based on their photometry, the unclassified companions are probably two mid-M dwarfs and one late-M/early-L dwarf. One of the T8 companions, WISE J142320.84+011638.0, has already been reported by Pinfield and coworkers. The other T8 companion, ULAS J095047.28+011734.3, was discovered by Burningham and coworkers through the United Kingdom Infrared Telescope Infrared Deep Sky Survey, but its companionship has not been previously recognized in the literature. The L5 companion, 2MASS J17430860+8526594, is a new member of a class of L dwarfs that exhibit unusually blue near-IR colors. Among the possible mechanisms that have been previously proposed for the peculiar colors of these L dwarfs, low metallicity does not appear to be a viable explanation for 2MASS J17430860+8526594 since our spectrum of the primary suggests that its metallicity is not significantly subsolar

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

The human monoclonal antibody otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a key driver in immune-mediated inflammatory conditions. We aimed to evaluate the efficacy, safety, and key patient-reported outcomes related to pain in patients with active rheumatoid arthritis receiving otilimab. Methods. This phase 2b, dose-ranging, multicentre, placebo-controlled study was done at 64 sites across 14 countries. Patients aged 18 years or older with rheumatoid arthritis who were receiving stable methotrexate were randomly assigned (1:1:1:1:1:1) to subcutaneous placebo or otilimab 22·5 mg, 45 mg, 90 mg, 135 mg, or 180 mg, plus methotrexate, once weekly for 5 weeks, then every other week until week 50. The randomisation schedule was generated by the sponsor, and patients were assigned to treatment by interactive response technology. Randomisation was blocked (block size of six) but was not stratified. Investigators, patients, and the sponsor were blinded to treatment. An unblinded administrator prepared and administered the study drug. The primary endpoint was the proportion of patients who achieved disease activity score for 28 joints with C-reactive protein (DAS28-CRP) 3·2 (week 24) escaped to otilimab 180 mg. Patients who escaped were treated as non-responders in their original assigned group. Safety endpoints were incidence of adverse events and serious adverse events, infections, and pulmonary events. Efficacy and safety outcomes were assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02504671. Findings.Between July 23, 2015, and Dec 29, 2017, 222 patients were randomly assigned (37 to each group). 86 (49%) of 175 escaped to otilimab 180 mg at week 12 and 57 (69%) of 83 at week 24. At week 24, the proportion of patients with DAS28-CRP <2·6 was two (5%) of 37 in the otilimab 22·5 mg group, six (16%) of 37 in the 45 mg group, seven (19%) of 37 in the 90 mg group, five (14%) of 37 in the 135 mg group, five (14%) of 37 in the 180 mg, and one (3%) of 37 in the placebo group. The largest difference was achieved with otilimab 90 mg (16·2%; odds ratio [OR] 8·39, 95% CI 0·98–72·14; p=0·053). Adverse events were reported pre-escape in 19–24 (51–65%) patients and post escape in 10–17 (40–61%) patients across otilimab dose groups and in 18 (49%) of 37 and 22 (67%) of 33 in the placebo group. The most common adverse event was nasopharyngitis: 3–9 (8–24%) in otilimab groups and one (3%) in the placebo group pre-escape and 1–3 (4–10%) in otilimab groups and seven (21%) in the placebo group post escape. Pre-escape serious adverse events were foot fracture (otilimab 45 mg); arthralgia, myocardial infarction, dizziness (otilimab 90 mg); oesophageal spasm, acute pyelonephritis (otilimab 22·5 mg), and uterine leiomyoma (otilimab 135 mg). Post-escape serious adverse events were ankle fracture (placebo) and rheumatoid arthritis (otilimab 135 mg). There were no deaths or pulmonary events of clinical concern, and rates of serious infection were low. Interpretation. Otilimab plus methotrexate was well tolerated and, despite not achieving the primary endpoint of DAS28-CRP remission, there were improvements compared with placebo in disease activity scores. Of note, patients reported significant improvement in pain and physical function, supporting further clinical development of otilimab in rheumatoid arthritis

Forage seeding in rangelands increases production and prevents weed invasion

Increasing forage productivity in the Sierra foothill rangelands would help sustain the livestock industry as land availability shrinks and lease rates rise, but hardly any studies have been done on forage selections. From 2009 to 2014, in one of the first long-term and replicated studies of seeding Northern California's Mediterranean annual rangeland, we compared the cover of 22 diverse forages to determine their establishment and survivability over time. Among the annual herbs, forage brassica (Brassica napus L.) and chicory (Cichorium intybus L.) proved viable options. Among the annual grasses, soft brome (Bromus hordeaceus) and annual ryegrass (Lolium multiflorum) performed well. However, these species will likely require frequent reseeding to maintain dominance. Long-term goals of sustained dominant cover (> 3 years) are best achieved with perennial grasses. Perennial grasses that persisted with greater than 50% cover were Berber orchardgrass (Dactylis glomerata), Flecha tall fescue (Lolium arundinaceum) and several varieties of hardinggrass (Phalaris aquatica L., Perla koleagrass, Holdfast, Advanced AT). In 2014, these successful perennials produced over three times more dry matter (pounds per acre) than the unseeded control and also suppressed annual grasses and yellow starthistle (Centaurea solstitialis L.) cover

Limited Vegetation Development on a Created Salt Marsh Associated with Over-Consolidated Sediments and Lack of Topographic Heterogeneity

Restored salt marshes frequently lack the full range of plant communities present on reference marshes, with upper marsh species underrepresented. This often results from sites being too low in the tidal frame and/or poorly drained with anoxic sediments. A managed coastal realignment scheme at Abbotts Hall, Essex, UK, has oxic sediments at elevations at which upper marsh communities would be expected. But 7 years after flooding, it continued to be dominated by pioneer communities, with substantial proportions of bare ground, so other factors must hinder vegetation development at these elevations. The poorly vegetated areas had high sediment shear strength, low water and organic carbon content and very flat topography. These characteristics occur frequently on the upper parts of created marshes. Experimental work is required to establish causal links with the ecological differences, but other studies have also reported that reduced plant β-diversity and lower usage by fish are associated with topographic uniformity. Uniformity also leads to very different visual appearance from natural marshes. On the upper intertidal, sediment deposition rate are slow, water velocities are low and erosive forces are weak. So, topographic heterogeneity cannot develop naturally, even if creeks have been excavated. Without active management, these conditions will persist indefinitely

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Forage seeding in rangelands increases production and prevents weed invasion

Increasing forage productivity in the Sierra foothill rangelands would help sustain the livestock industry as land availability shrinks and lease rates rise, but hardly any studies have been done on forage selections. From 2009 to 2014, in one of the first long-term and replicated studies of seeding Northern California's Mediterranean annual rangeland, we compared the cover of 22 diverse forages to determine their establishment and survivability over time. Among the annual herbs, forage brassica (Brassica napus L.) and chicory (Cichorium intybus L.) proved viable options. Among the annual grasses, soft brome (Bromus hordeaceus) and annual ryegrass (Lolium multiflorum) performed well. However, these species will likely require frequent reseeding to maintain dominance. Long-term goals of sustained dominant cover (&gt; 3 years) are best achieved with perennial grasses. Perennial grasses that persisted with greater than 50% cover were Berber orchardgrass (Dactylis glomerata), Flecha tall fescue (Lolium arundinaceum) and several varieties of hardinggrass (Phalaris aquatica L., Perla koleagrass, Holdfast, Advanced AT). In 2014, these successful perennials produced over three times more dry matter (pounds per acre) than the unseeded control and also suppressed annual grasses and yellow starthistle (Centaurea solstitialis L.) cover

Russian thistle (Salsola spp.) control in California rangelands over five years

Russian thistle, also known as tumbleweed (Salsola spp.), is a problematic invasive plant found on natural and working landscapes. On a California rangeland, we tested the singular and interactive treatments of grazing, herbicide and seeding to determine how these approaches might influence Salsola cover across a five year experiment. Total Salsola cover declined by 3% annually during the study. A single spring treatment of chlorsulfuron + 2,4-D followed by glyphosate applied in the fall just prior to seeding, and then 2,4-D the following spring, significantly reduced Salsola cover compared to the untreated control. Seeded forage species cover increased over time and was significantly higher than seeded native species cover five years after seeding. However, the seeding treatment had no effect on Salsola cover. Although grazing did not reduce Salsola cover, due to the beneficial effects of grazing on reducing other non-native species, this study supports the use of an integrated approach of herbicide application, grazing and seeding to achieve management goals on an arid working landscape.Open access articleThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]